Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
The challenge of defining a neural population
Our current approach is largely arbitrary. We need new methods for grouping cells, ideally by their dynamics.
The challenge of defining a neural population
Our current approach is largely arbitrary. We need new methods for grouping cells, ideally by their dynamics.
Oxytocin prompts prairie voles to oust outsiders, fortifying their friendships
The “love hormone” drives the neurobiology behind platonic bonds in animals usually studied for their romantic attachments.
Oxytocin prompts prairie voles to oust outsiders, fortifying their friendships
The “love hormone” drives the neurobiology behind platonic bonds in animals usually studied for their romantic attachments.
Contested paper on vaccines, autism in rats retracted by journal
The editor-in-chief cited “inconsistencies in the number of subjects” as the reason for the retraction.
Contested paper on vaccines, autism in rats retracted by journal
The editor-in-chief cited “inconsistencies in the number of subjects” as the reason for the retraction.